Androgens and chronic obstructive pulmonary disease

Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):257-61. doi: 10.1097/MED.0b013e3283369da6.

Abstract

Purpose of review: To evaluate the recent literature on the effect of the use of androgens in men with chronic obstructive pulmonary disease (COPD).

Recent findings: Men with COPD have been found to have reduced endogenous testosterone levels in some studies, and they also share several traits with hypogonadal men, such as loss of lean body mass and strength, suggesting that substitution with androgens might be a rational therapy. There are, however, only a few published placebo-controlled trials investigating the effects of androgens in men with COPD, and only one during the last 2 years. After a review of these manuscripts they were summarized.

Summary: The effect of androgens in men with COPD is modest, and pulmonary function was in general not improved in men using androgens. The use of androgens to increase muscle mass and strength in patients participating in rehabilitation programs is promising, and also regarding the beneficial effects on sexuality. However, more research is needed to determine if androgen therapy could be a treatment option for men with COPD.

Publication types

  • Review

MeSH terms

  • Androgens / therapeutic use*
  • Body Mass Index
  • Humans
  • Male
  • Muscle Strength / physiology
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Sexuality / physiology
  • Treatment Outcome

Substances

  • Androgens